Analyst Research

Report Title Price
Provider: GlobalData
$125.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Wright Reports
$75.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Ranbaxy Laboratories Ltd Import Ban; USFDA Found Suspected Hair, Oil In Tablets-Business Standard


Wednesday, 18 Sep 2013 09:30am EDT 

Business Standard reported that tablets embedded with black fibre that was suspected to be hair from an employee's arm, black spots of oil from machines in tablets and absence of running water in toilets were some observations made by USFDA that has banned import of drugs made at Ranbaxy Laboratories Ltd's Mohali unit. According to USFDA documents sent to Ranbaxy's Mohali plant head after a series of inspections in 2011 and 2012, the US health regulator made 11 observations citing various violations of current good manufacturing practices (cGMP). 

Company Quote

614.85
8.85 +1.46%
5:27am EST